The reasons accounting for the lack of in vivo antitumor evaluations include the relatively restricted Gasdermin protein expression in tumor cells, the complication of initiating Gasdermin-mediated tumor cell pyroptosis requiring activation of multiple signaling pathways to unleash the pore-forming domain of Gasdermin proteins, and the presence of ESCRT III machinery-dependent membrane repair9. Here, GSDMA is linked to neoplasm.